Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Specializing In
- Cellular Immunotherapy
- Chemotherapy
Biography
Dr. Sidana is a hematologist/oncologist who is fellowship trained in advanced hematology with an emphasis on myeloma, amyloidosis, and dysproteinemia disorders. She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine. She leads the Myeloma Cellular Immunotherapy program at Stanford.
Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life.
Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients’ access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients’ quality of life and cognitive function.
Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.
In the past, Dr. Sidana received Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research on the impact of clinical trial participation on patients with multiple myeloma and lymphoma. She has also received grants from the Amyloidosis Foundation and International Waldenstrom’s Macrogloulinemia Foundation to understand AL amyloidosis, a rare disease caused by buildup of an abnormal protein.
Dr. Sidana has given presentations at regional and national conferences and her work has been published in high-impact journals.
Dr. Sidana has been recognized for her work with many honors, including an Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic.
She is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy. Dr. Sidana is often an invited speaker at patient support groups as well as symposia and workshops for her peers.
Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life.
Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients’ access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients’ quality of life and cognitive function.
Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.
In the past, Dr. Sidana received Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research on the impact of clinical trial participation on patients with multiple myeloma and lymphoma. She has also received grants from the Amyloidosis Foundation and International Waldenstrom’s Macrogloulinemia Foundation to understand AL amyloidosis, a rare disease caused by buildup of an abnormal protein.
Dr. Sidana has given presentations at regional and national conferences and her work has been published in high-impact journals.
Dr. Sidana has been recognized for her work with many honors, including an Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic.
She is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy. Dr. Sidana is often an invited speaker at patient support groups as well as symposia and workshops for her peers.
View Full Biography
Professional Summary
Education & Certifications
- Fellowship, Mayo Clinic, Rochester, MN, Myeloma, Amyloidosis and Related Disorders (Advanced Hematology)
- Fellowship, Mayo Clinic, Rochester, MN, Hematology and Oncology
- Residency, Cleveland Clinic, OH, Internal Medicine
- Medical Education, Maulana Azad Medical College, University of Delhi, India
Honors & Awards
- "NextGen Innovator", HemOnc Today (2017)
- Abstract Achievement Award, American Society of Hematology (2016)
- Clinical Research Training Institute, American Society of Hematology (2017)
- Dean's Roll of Honor for best academic performance, Maulana Azad Medical College, University of Delhi (2008)
- Gold Medal, best academic performance in Internal Medicine, Maulana Azad Medical College, University of Delhi (2010)
- Hematology/Oncology Outstanding Fellow, Mayo Clinic, Rochester, MN (2018)
- Junior Researcher Travel Award, Amyloidosis Foundation (2018)
- Lt. Governer's Rolling Trophy - Best student in medical school graduating class, Maulana Azad Medical College, University of Delhi (2010)
- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2019)
- Methods in Clinical Cancer Research Workshop, Vail, CO, American Association of Cancer Research/American Society of Clinical Oncology (2016)
- Outstanding Fellow Award, Minnesota Society of Clinical Oncology (2017)
- Outstanding Research Fellow, Department of Medicine, Mayo Clinic, Rochester, MN (2018)
- Research Grant (Co-Principal Investigator), International Waldenstrom's Macroglobulinemia Foundation (2017)
- Research Grant for Early Career Investigators, Amyloidosis Foundation (2018)
- Young Investigator Award, 10th International Workshop on Waldenstrom's Macroglobulinemia (2018)
- Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
Memberships
- Member, Biomarkers Committee, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (2020 - Present)
- Member, Editor Search Committee, American Society of Hematology (2019 - Present)
- Co-Chair, Taskforce on trainees and junior faculty, American Society of Transplantation and Cellular Therapy (2019 - Present)
- Member, Protocol Writing Committee, BMT CTN 1901/1902, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (2019 - Present)
- Member, Professional Development Committee, American Society of Clinical Oncology (2018 - 2019)
- Member, Chair 2018-19 term, Trainee and Early Career Council, American Society of Clinical Oncology (2017 - Present)
- Member, Trainee Council and Liaison to Communications Committee, American Society of Hematology (2017 - 2019)
- Member, European Hematology Association (2019 - Present)
- Member, International Society of Amyloidosis (2017 - Present)
- Member, International Myeloma Society (2016 - Present)
Publications
-
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis
Al Saleh, A. S., Sidiqi, M. H., Sidana, S., Muchtar, E., Dispenzieri, A., Dingli, D., … Gertz, M. A. (2019). Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. AMERICAN JOURNAL OF HEMATOLOGY, 1066–71. -
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
Sidana, S., Sidiqi, M. H., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Muchtar, E., … Gertz, M. A. (2019). Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. AMERICAN JOURNAL OF HEMATOLOGY. -
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses
McCarter, S. J., Vijayvargiya, P., Sidana, S., Nault, A. M., Lane, C. E., Lehman, J. S., … Al-Kali, A. (2019). A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. LEUKEMIA & LYMPHOMA, 60(2), 559–61. -
Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Ramirez-Alvarado, M., Murray, D. L., … Leung, N. (2019). Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 185(4), 701–7. -
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
Tandon, N., Sidana, S., Rajkumar, S. V., Gertz, M. A., Buadi, F. K., Lacy, M. Q., … Kumar, S. K. (2019). Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. BLOOD ADVANCES, 3(5), 744–50. -
Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis
Sidana, S., Tandon, N., Brady, P. A., Grogan, M., Gertz, M. A., Dispenzieri, A., … Kourelis, T. (2019). Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. MAYO CLINIC PROCEEDINGS, 94(3), 455–64. -
Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Greipp, P. T., Baughn, L. B., … Kumar, S. K. (2019). Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. AMERICAN JOURNAL OF HEMATOLOGY, 94(5), E117–E120. -
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Dispenzieri, A., Gertz, M. A., … Kumar, S. K. (2019). Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. AMERICAN JOURNAL OF HEMATOLOGY, 94(4), 424–30. -
Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty, R., Sidana, S., Shah, G. L., Scordo, M., Hamilton, B. K., & Majhail, N. S. (2019). Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 25(5), e155–e162. -
Should we measure clonal circulating plasma cells in light chain amyloidosis?
Sidana, S., Kumar, S. K., & Gonsalves, W. I. (2018). Should we measure clonal circulating plasma cells in light chain amyloidosis? Oncotarget, 9(86), 35607–8. -
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., … Kumar, S. K. (2019). Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. LEUKEMIA, 33(3), 730–38. -
Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia
Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M. A., Dispenzieri, A., Muchtar, E., … Kapoor, P. (2019). Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. LEUKEMIA, 33(3), 790–94. -
59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly
Orme, J. J., Sidana, S., & Gonsalves, W. I. (2018). 59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. MAYO CLINIC PROCEEDINGS, 93(10), 1525–29. -
Reply to A. Piccardo et al, E. Hindie et al, MC Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Gerds, A. T., Carraway, H. E., Kalaycio, M., … Mukherjee, S. (2018). Reply to A. Piccardo et al, E. Hindie et al, MC Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al. JOURNAL OF CLINICAL ONCOLOGY, 36(18), 1889-+. -
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Dingli, D., Jevremovic, D., … Gonsalves, W. I. (2018). Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. LEUKEMIA, 32(6), 1421–26. -
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., … Mukherjee, S. (2018). Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(18), 1831-+. -
The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Rajkumar, S. V., & Kumar, S. K. (2018). The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. LEUKEMIA, 32(5), 1243–46. -
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., … Kumar, S. K. (2018). Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. BONE MARROW TRANSPLANTATION, 53(3), 326–33. -
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
Tandon, N., Sidana, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Dingli, D., … Kumar, S. K. (2018). Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). AMERICAN JOURNAL OF HEMATOLOGY, 93(1), 17–22. -
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis
Tandon, N., Sidana, S., Rajkumar, S. V., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., … Kumar, S. K. (2017). Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24(3), 183–88. -
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
Sidana, S., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., … Kumar, S. K. (2017). Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. AMERICAN JOURNAL OF HEMATOLOGY, 92(7), 668–73. -
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis
Tandon, N., Sidana, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Buadi, F. K., … Kumar, S. K. (2017). Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. AMERICAN JOURNAL OF HEMATOLOGY, 92(6), 549–54. -
Prevalence of depression in students of a medical college in New Delhi: A cross-sectional study
Sidana, S., Kishore, J., Ghosh, V., Gulati, D., Jiloha, R. C., & Anand, T. (2012). Prevalence of depression in students of a medical college in New Delhi: A cross-sectional study. AUSTRALASIAN MEDICAL JOURNAL, 5(5), 247–50. -
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., … Kumar, S. K. (2018). Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia, 32(3), 729–35. -
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Tandon, N., Muchtar, E., Sidana, S., Dispenzieri, A., Lacy, M. Q., Dingli, D., … Gertz, M. A. (2017). Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 52(8), 1126–32. -
Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
Molenaar, R. J., Pleyer, C., Radivoyevitch, T., Sidana, S., Godley, A., Advani, A. S., … Mukherjee, S. (2018). Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia, 32(4), 952–59. -
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
Sidana, S., Narkhede, M., Elson, P., Hastings, D., Faiman, B., Valent, J., … Reu, F. J. (2017). Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PloS One, 12(3), e0172996. -
Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.
Chaturvedi, S., Sidana, S., Elson, P., Khorana, A. A., & McCrae, K. R. (2014). Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PloS One, 9(8), e94048. -
Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient.
Sidana, S., Madanat, Y., & Pile, J. (2015). Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient. Journal of General Internal Medicine, 30(4), 529–30. -
CAR T-cell therapy: is it prime time in myeloma?
Sidana, S., & Shah, N. (2019). CAR T-cell therapy: is it prime time in myeloma? Blood Advances, 3(21), 3473–80. -
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
Muchtar, E., Gertz, M. A., Kourelis, T. V., Sidana, S., Go, R. S., Lacy, M. Q., … Dispenzieri, A. (2019). Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. -
Revisiting complete response in light chain amyloidosis.
Sidana, S., Dispenzieri, A., Murray, D. L., Go, R. S., Buadi, F. K., Lacy, M. Q., … Kumar, S. K. (2019). Revisiting complete response in light chain amyloidosis. Leukemia. -
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana, S., Larson, D. P., Greipp, P. T., He, R., McPhail, E. D., Dispenzieri, A., … Gertz, M. A. (2019). IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. -
CAR T-cell therapy: is it prime time in myeloma?
Sidana, S., & Shah, N. (2019). CAR T-cell therapy: is it prime time in myeloma? Hematology. American Society of Hematology. Education Program, 2019(1), 260–65. -
Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?
Sidana, S., & Manasanch, E. (2019). Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? Hematology. American Society of Hematology. Education Program, 2019(1), 142–47. -
Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis.
Sidana, S., Muchtar, E., Sidiqi, M. H., Jevremovic, D., Dispenzieri, A., Gonsalves, W., … Kumar, S. K. (2020). Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis. American Journal of Hematology. -
Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana, S., Milani, P., Binder, M., Basset, M., Tandon, N., Foli, A., … Kumar, S. K. (2020). A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 10(4), 41. -
Glycosylation of Immunoglobulin Light Chains is Highly Prevalent in Cold Agglutinin Disease.
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Muchtar, E., Willrich, M. A., … Gertz, M. A. (2020). Glycosylation of Immunoglobulin Light Chains is Highly Prevalent in Cold Agglutinin Disease. American Journal of Hematology. -
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.
Abdallah, N., Sidana, S., Dispenzieri, A., Lacy, M., Buadi, F., Hayman, S., … Kumar, S. (2020). Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation. -
Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?
Sidana, S., & Manasanch, E. (2019). Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 142–47. -
CAR T-cell therapy: is it prime time in myeloma?
Sidana, S., & Shah, N. (2019). CAR T-cell therapy: is it prime time in myeloma? HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 260–65. -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Costa, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., … Paiva, B. (2020). International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. -
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Outcomes with different administration schedules of Bortezomib in Bortezomib, Lenalidomide and dexamethasone (VRd) as first-line therapy in Multiple Myeloma.
Cook, J., Johnson, I., Higgins, A., Sidana, S., Warsame, R., Gonsalves, W., … Kumar, S. (2020). Outcomes with different administration schedules of Bortezomib in Bortezomib, Lenalidomide and dexamethasone (VRd) as first-line therapy in Multiple Myeloma. American Journal of Hematology. -
Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., … Liedtke, M. (2019). Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis. BLOOD. AMER SOC HEMATOLOGY. -
Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., … Liedtke, M. (2019). Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses. BLOOD. AMER SOC HEMATOLOGY. -
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Sidana, S., Dasari, S., Kourelis, T., Dispenzieri, A., Murray, D. L., King, R. L., … Gertz, M. A. (2019). Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. BLOOD, 134. -
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Willrich, M. A., Snyder, M., … Gertz, M. A. (2019). Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. BLOOD, 134. -
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Sidana, S., Thanarajasingam, G., Griffin, J., Thompson, C. A., Burtis, M., Warsame, R., … Dueck, A. C. (2019). Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. BLOOD, 134. -
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort.
Drosou, M. E., Vaughan, L. E., Muchtar, E., Buadi, F. K., Dingli, D., Dispenzieri, A., … Leung, N. (2021). Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. American Journal of Hematology. -
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).
Sidana, S., Allmer, C., Larson, M. C., Dueck, A. C., Yost, K. J., Warsame, R. M., … Kumar, S. (2020). Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., … Richardson, P. G. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet. Oncology, 22(3), e105–e118. -
Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya, H., & Sidana, S. (2021). Antibody-Based Treatment Approaches in Multiple Myeloma. Current Hematologic Malignancy Reports. -
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Moreau, P., Kumar, S. K., Miguel, J. S., Davies, F., Zamagni, E., Bahlis, N., … Richardson, P. G. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. LANCET ONCOLOGY, 22(3), E105–E118. -
IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.
Sidana, S., Dasari, S., Kourelis, T. V., Dispenzieri, A., Murray, D. L., King, R. L., … Gertz, M. A. (2021). IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. Blood Advances, 5(8), 2101–5. -
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances. -
Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giralt, S., Agrawal, V., … D'Souza, A. (2021). Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475. -
Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy. -
Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Popat, R., Usmani, S. Z., Garfall, A., van de Donk, N., Nahi, H., San-Miguel, J. F., … Krishnan, A. (2022). Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. BRITISH JOURNAL OF HAEMATOLOGY. WILEY. -
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R. A., Dueck, A. C., … Habermann, T. M. (2022). Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet. Haematology, 9(5), e374–e384. -
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
Kansagra, A., Dispenzieri, A., Fraser, R., Estrada-Merly, N., Sidana, S., Nishihori, T., … D'Souza, A. (2022). Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances. -
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy vs Autologous and Allogeneic Stem Cell Transplant.
Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., … Kumar, S. (2022). Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy vs Autologous and Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. -
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.
Sidana, S., Allmer, C., Larson, M. C., Dueck, A., Yost, K., Warsame, R., … Kumar, S. K. (2022). Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, OP2100789. -
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau, P., Garfall, A. L., van de Donk, N. W., Nahi, H., San-Miguel, J. F., Oriol, A., … Usmani, S. Z. (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England Journal of Medicine. -
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R. A., Dueck, A. C., … Habermann, T. M. (2022). Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. LANCET HAEMATOLOGY, 9(5), E374–E384. -
Early cytopenias and infections after standard of care idecabtagene vicleucel?in relapsed or refractory multiple myeloma.
Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., … Hansen, D. K. (2022). Early cytopenias and infections after standard of care idecabtagene vicleucel?in relapsed or refractory multiple myeloma. Blood Advances. -
Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., … Miklos, D. B. (2021). Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY. -
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., … Sidana, S. (2021). Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study. BLOOD. AMER SOC HEMATOLOGY. -
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Mailankody, S., Liedtke, M., Sidana, S., Matous, J. V., Chhabra, S., Oluwole, O. O., … Hari, P. (2021). Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY. -
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau, P., Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J., … Krishnan, A. Y. (2021). Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY. -
Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.
Kourelis, T., Bansal, R., Patel, K. K., Berdeja, J. G., Raje, N. S., Alsina, M., … Lin, Y. (2022). Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Hansen, D. K., Sidana, S., Peres, L., Shune, L., Sborov, D. W., Hashmi, H., … Patel, K. K. (2022). Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., … Patel, K. K. (2023). Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201365. -
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., … Kumar, S. K. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature Medicine. -
Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience.
Kourelis, T., Bansal, R., Berdeja, J., Siegel, D., Patel, K., Mailankody, S., … Lin, Y. (2023). Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience. Transplantation and Cellular Therapy. -
Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., … Kurtz, D. M. (2022). Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA. BLOOD. AMER SOC HEMATOLOGY. -
Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Mailankody, S., Matous, J., Liedtke, M., Sidana, S., Oluwole, O. O., Mohan, M., … Kumar, S. K. (2022). Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY. -
Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
Peres, L. C., Oswald, L. B., Dillard, C., De Avila, G., Nishihori, T., Blue, B. J., … Patel, K. (2022). Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy. BLOOD. AMER SOC HEMATOLOGY. -
Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience
Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O. A. C., Freeman, C. L., De Avila, G., … Alsina, M. (2022). Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY. -
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma CAR T Consortium Real World Experience
Khouri, J., Li, H., Hansen, D. K., Sidana, S., Shune, L. O., DeJarnette, S., … Patel, K. (2022). Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma CAR T Consortium Real World Experience. BLOOD. AMER SOC HEMATOLOGY. -
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma, N., Dhakal, B., Fraser, R., Estrada-Merly, N., Anderson, K., Freytes, C. O., … Sidana, S. (2023). Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. -
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Moreau, P., van de Donk, N. W., Nahi, H., Oriol, A., Nooka, A. K., Martin, T., … Usmani, S. Z. (2023). Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma. Future Oncology (London, England). -
Reply to R. Chakraborty et al.
Hansen, D. K., Sidana, S., Peres, L. C., & Patel, K. K. (2023). Reply to R. Chakraborty et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2300568. -
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V. V., … Einsele, H. (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. The New England Journal of Medicine. -
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.
Hosoya, H., Rodriguez-Otero, P., Sidana, S., & Borrello, I. M. (2023). Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 43, e389860. -
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri, C. J., Hildebrandt, M. A., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., … Castaneda Puglianini, O. A. (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal, 13(1), 117. -
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Dhakal, B., Yong, K., Harrison, S. J., Mateos, M.-V., Moreau, P., van de Donk, N. W. C. J., … Einsele, H. (2023). First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., … Hansen, D. K. (2023). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. -
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.
Gertz, M., Abonour, R., Gibbs, S. N., Finkel, M., Landau, H., Lentzsch, S., … Broder, M. S. (2023). Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis. ClinicoEconomics and Outcomes Research : CEOR, 15, 673–680. -
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Hansen, D. K., Patel, K. K., Peres, L. C., Kocoglu, M. H., Shune, L., Simmons, G., … Sidana, S. (2023). Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Afrough, A., Hashmi, H., Hansen, D. K., Sidana, S., Ahn, C., Dima, D., … Lin, Y. (2023). Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, N. W. C. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., … Sidana, S. (2023). Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., … Janakiram, M. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 13(1), 158.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
- Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(34 reviews)
Great Doctor
I like her very much. She is professional and friendly and has helped me a great deal.
I like that she is very confident and to the point in her Communication with me.
Excellent
I am very grateful to have Dr. Sidana's excellent care.
Dr sidana reviewed everything and listened
Very reliable and helpful
Dr Sidana is thoughtful. I have great confidence in her ability. I also very much appreciate her willingness to plan ahead for the stages of the delivery of this therapy.
Dr Sidana is a thoughtful and caring doctor. I have been extremely happy with her care...
Dr. Sidana was very helpful and answered all my questions clearly. I was very pleased with our interaction.
She was impressive: very clear, reassuring, knowledgeable, and compassionate.
Dr. Sidana is always very personable and helpful.
Excellent Doctor!!
It is great working with you!
Dr Sidana was very personable, and she gave me plenty of time to think and ask questions.
I look forward to being her patient.
She seems super capable
She offered me a chance at upcoming trials that could make a difference in treating my cancer. I am very grateful for her attention to my particular needs for treatment.
Dr. Sidana and the team are professional, compassionate and extremely competent.
Appreciate her expertise and consult.
She is very concerned about my progress and gave me all the info I needed
Dr Sidana is the best. She is extremely brilliant and is a very caring provider. I owe her my life.
Dr. Sidana is great.
She is an excellent doctor and very knowledgeable about latest developments in treatment of myeloma. I am fortunate she is one of my doctors.
Very informative! Lot of things we did not know . Very professional
Very knowledgeable oncologist. Apologize I thought visit was to be with diabetic neutrtionist. Glad it was with Dr Sidana. As she is following and in agreement with oncologist here in eureka ca. thanx you.
Excellent
Dr. Sidana is compassionate, understanding knowledgeable and very helpful.
I’m still hoping for the best with my treatment but understand that I may or may not got beyond a few years before multiple myeloma returns.
Seemed very knowledgeable and personable. However, the greater portion of the video visit was with a different doctor.
She is a fantastic doctor and her team, Lenny and Leslie, are excellent too.
Dr Sidana is fine. I would highly prefer to meet with her in person, rather than through a cheap, telemedicine video call. This practice contributes to the gradual erosion of what used to be a high qua;ity pateint experience with Stanford University.
Very helpful and helped me understand upcoming treatment
Excellent physician. I’m lucky to have her caring for me.
I am very happy to have Dr Sidana helping me.
I found Dr. Sidana to be extremely knowledgeable, which was no surprise, but also totally approachable. Sometimes experts can risk seeming condescending, but Dr. Sidana was anything but. I felt she listened carefully and responded fully, taking great pains to clarify anything I was having difficulty following. I also appreciated her willingness to be direct about the dangers and uncertainties associated with the stem cell transplant process. All in all, I left the session much more optimistic about going forward with transplantation that I anticipated. One of my key goals in going into the session was to see what kind of response I felt towards Dr. Sidana, both as a doctor and a person. I couldn't have been more impressed and reassured.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records